New data reveal that episodic lack of disease control in chronic spontaneous urticaria is linked to increased hospitalizations and outpatient visits.

Lebrikizumab is an interleukin-13 antagonist approved as Ebglyss for the treatment of adults and pediatric patients with moderate to severe atopic dermatitis.

The data suggest significant challenges in maintaining long-term disease control with advanced systemic therapies for atopic dermatitis.

Asthma exacerbation risk appeared to be reduced in patients receiving treatment with certain immune checkpoint inhibitors (ICIs), according to study results presented at the American Academy of ...

A systematic review shows second generation antihistamines appear to be more effective and less sedating for patients managing chronic urticaria.

Montelukast is a leukotriene receptor antagonist approved for the prophylactic and chronic treatment of asthma and the relief of allergic rhinitis.

COVID vaccines are back under review and the move is raising concern among some health experts. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is slated ...

The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.

Novo Nordisk announced Tuesday that it will cut US list prices of Ozempic and Wegovy by up to 50% starting next year. The ...

Findings based on comparison to glycopyrrolate-formoterol and tiotropium-olodaterol in patients newly prescribed LAMA-LABA inhalers.

Results from ADAPT OCULUS are expected to support a sBLA submission to the FDA to secure a label expansion for oMG.

Clinicians now have an FDA-approved liquid desmopressin option for central diabetes insipidus, designed for dosing consistency across the age spectrum.